Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.

Aghemo A, Rumi MG, De Nicola S, Colombo M.

Hepatology. 2010 Sep;52(3):1170-1. doi: 10.1002/hep.23685. No abstract available.

PMID:
20812363
2.

Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.

Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, Ikeda K, Akuta N, Hosaka T, Kobayashi M, Kumada H.

J Med Virol. 2005 Jan;75(1):27-34.

PMID:
15543591
3.

Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.

Pattullo V, Ravindran NC, Mazzulli T, Wong DK, Heathcote EJ.

J Viral Hepat. 2010 Dec;17(12):834-8. doi: 10.1111/j.1365-2893.2010.01248.x.

PMID:
20196800
4.

[Predictive value of virological response on sustained virological response in hepatitis C patients].

Zhou YQ, Wang XH, Fan Y, Zhu Y, Tan WT, Mao Q.

Zhonghua Gan Zang Bing Za Zhi. 2009 Dec;17(12):944-6. Chinese. No abstract available.

PMID:
20038340
5.

Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.

Roomer R, van Vuuren AJ, Schutten M, Heijens A, Janssen HL, de Knegt RJ.

Antivir Ther. 2011;16(5):771-4. doi: 10.3851/IMP1777.

PMID:
21817199
6.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
7.

Response-guided therapy: optimizing treatment now and in the future.

Marcellin P, Rizzetto M.

Antivir Ther. 2008;13 Suppl 1:1-2. No abstract available.

PMID:
18432156
8.

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.

Harrison SA, Rossaro L, Hu KQ, Patel K, Tillmann H, Dhaliwal S, Torres DM, Koury K, Goteti VS, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS.

Hepatology. 2010 Sep;52(3):864-74. doi: 10.1002/hep.23787.

PMID:
20568303
9.

Peginterferon and ribavirin for chronic hepatitis C.

Hoofnagle JH, Seeff LB.

N Engl J Med. 2006 Dec 7;355(23):2444-51. Review. No abstract available.

PMID:
17151366
10.

Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.

Lukasiewicz E, Hellstrand K, Westin J, Ferrari C, Neumann AU, Pawlotsky JM, Schalm SW, Zeuzem S, Veldt BJ, Hansen BE, Verhey-Hart E, Lagging M.

Hepatology. 2007 Jan;45(1):258-9. No abstract available.

PMID:
17187414
11.

Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy).

Halfon P, Pérusat S, Bourlière M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chêne G, Couzigou P; ANRS HC16 GAMMATRI Study Group..

J Med Virol. 2010 Dec;82(12):2027-31. doi: 10.1002/jmv.21909.

PMID:
20981789
12.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
13.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

14.

[Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].

Li MH, Chen LJ, Qiu GH, Lu Y, Xie Y, Xu DZ.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):497-500. Chinese.

PMID:
19912682
15.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
16.

Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors.

Shirakawa H, Matsumoto A, Joshita S, Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K, Tanaka E; Nagano Interferon Treatment Research Group..

Hepatology. 2008 Dec;48(6):1753-60. doi: 10.1002/hep.22543.

PMID:
18925643
17.

Optimal dosage of ribavirin.

Mangia A, Andriulli A.

Hepatology. 2010 Sep;52(3):1174. doi: 10.1002/hep.23742. No abstract available.

PMID:
20812365
18.

Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

Jessner W, Stauber R, Hackl F, Datz C, Watkins-Riedel T, Hofer H, Gangl A, Kessler H, Ferenci P.

J Viral Hepat. 2003 Jan;10(1):37-42.

PMID:
12558910
19.

Virological response in post-partum treated chronic hepatitis C women with pegylated interferon-alpha plus ribavirin. A case-control study.

Elefsiniotis IS, Pantazis KD, Magaziotou I, Bogris P, Mavrogiannis C.

J Clin Virol. 2004 Dec;31(4):314-5. No abstract available.

PMID:
15494277
20.

Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.

Yu ML, Dai CY, Huang JF, Chuang WL.

Hepatology. 2008 Sep;48(3):1019-20; author reply 1020-1. doi: 10.1002/hep.22434. No abstract available.

PMID:
18756469

Supplemental Content

Support Center